Published: January 15, 2019

Introduction {#sec1}
============

The microtubule-associated protein tau (MAPT; tau) is involved in the pathogenesis of several different forms of dementia, including Alzheimer's disease (AD), progressive supranuclear palsy, Pick's disease, corticobasal degeneration, and frontotemporal dementia (FTD) ([@bib35], [@bib48]). FTD is the third most common cause of dementia, after AD and vascular dementia ([@bib41]). Autosomal-dominant missense and splicing mutations in *MAPT* are causes of inherited or familial FTD (FTD-MAPT) ([@bib14], [@bib23], [@bib28]). However, although it is well established that these mutations lead to hyperphosphorylation and aggregation of tau protein *in vivo* ([@bib4], [@bib23]), the cell biology of neuronal dysfunction and progressive neurodegeneration in this condition are currently not fully understood.

In healthy neurons, tau protein is almost exclusively localized to the axon, and several mechanisms have been suggested for its highly polarized cellular localization, including selective mRNA and protein transport, local translation, and local degradation ([@bib53]). Mislocalization and aggregation of tau in neuronal cell bodies are common features of tau-mediated dementias, including FTD and AD ([@bib21], [@bib50], [@bib57]). Protein aggregation is widely considered as inherently pathogenic in neurodegeneration ([@bib17], [@bib26]), altering many cellular functions, most notably autophagy and proteostasis ([@bib5], [@bib9], [@bib37]). However, how *MAPT* mutations lead to tau hyperphosphorylation and mislocalization, the effects of this mislocalization on neuronal cell biology, and how this contributes to neuronal dysfunction and neurodegeneration all remain poorly understood.

As a typical microtubule-binding protein, tau has several roles in regulating microtubule function and intracellular transport ([@bib53]). Tau binds both alpha and beta tubulin subunits of microtubules and has been demonstrated to both stabilize and promote microtubule growth ([@bib31], [@bib56]). The presence of tau on microtubules can alter directions and rates of axonal transport ([@bib15], [@bib51]). Tau is a natively disordered protein and has recently been found to undergo fluid phase transitions at higher concentrations, nucleating microtubules when it does so ([@bib26]). Therefore, it is likely that the changes in tau levels, post-translational modifications, and cellular localization that occur in dementia lead to alterations in microtubule biology, particularly in the neuronal cell body.

To address the question of how *MAPT* mutations lead to neuronal dysfunction and neurodegeneration, we investigated the effects of two different classes of *MAPT* mutations on the cell biology of human iPSC-derived cortical neurons. We find that both missense and splicing *MAPT* mutations cause mislocalization of tau to the cell bodies of neurons and marked changes in microtubule dynamics. Microtubules in the cell bodies of FTD-MAPT neurons actively deform the nuclear membrane, disrupting nucleocytoplasmic transport. Defects in nuclear envelope function, including nucleocytoplasmic transport, are an important pathological process in ALS-FTD because of repeat expansions in *C9orf72* and *TDP-43* mutations ([@bib12], [@bib58], [@bib59], [@bib60]). Our findings demonstrate that dysfunction of the nuclear membrane due to altered microtubule dynamics is a pathogenic process in dementias involving tau, expanding the group of neurodegenerative diseases that involve disrupted nucleocytoplasmic transport and suggesting common mechanisms of neuronal dysfunctional in these heterogeneous conditions.

Results {#sec2}
=======

Increased Phosphorylation and Altered Cellular Localization of Tau in FTD-MAPT Neurons {#sec2.1}
--------------------------------------------------------------------------------------

To study the effects on neuronal cell biology of FTD-MAPT mutations, we generated excitatory cortical neurons ([@bib46]) from induced pluripotent stem cells (iPSCs) derived from individuals with different autosomal-dominant mutations in *MAPT* that are causal for early-onset FTD ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). We studied two different types of mutations: the *MAPT* IVS10+16 autosomal-dominant mutation, which increases inclusion of exon 10, encoding the second microtubule-binding repeat and thus altering the ratio of three (3R) and four (4R) tau isoforms ([@bib28], [@bib49]), and the autosomal-dominant *MAPT* P301L missense mutation that produces an aggregation-prone form of tau ([@bib53]) ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). The cortical identity of the neurons generated and the reproducibility of the culture compositions among genotypes was confirmed by assessing the expression of a set of classifier genes that define different neuronal cell types ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1Increased Phosphorylation and Altered Cellular Localization of Tau in FTD-MAPT Neurons(A) Phosphorylated tau (pS404; AT8 \[pS202/pT205\]) is increased as a fraction of total tau (epitope 243--441) in frontotemporal dementia (FTD)-MAPT neurons (*MAPT* IVS10+16-A/B and *MAPT* P301L) compared with non-demented and MAPT P301 isogenic control neurons (induced pluripotent stem cell \[iPSC\]-derived neurons at 120 days *in vitro* \[DIV\]; three biological replicates). β-actin and β3-tubulin were used as controls. Molecular weight (kDa) is indicated.(B) Tau isoforms with three (3R; red) or four (4R; inclusion of region 2; green) microtubule-binding regions were detected by western blot analysis of dephosphorylated protein extracts from iPSC-derived control and FTD-MAPT cortical neurons (120 DIV) and from post-mortem human cerebral cortex (non-demented individual). Tau isoforms were identified relative to a commercial tau ladder (Sigma). Molecular weight (kDa) is indicated.(C) Peptide sequences identified by tau immunoprecipitation (IP)/mass spectrometry from iPSC-derived cortical neurons, confirming the inclusion of repeat 2 (corresponding to exon 10) of 4R tau. In *MAPT* P301L neurons, both proline and leucine were identified at position 301 (highlighted red). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.(D) Tau protein is mislocalized to MAP2-positive cell bodies and dendrites in iPSC-derived FTD-MAPT neurons. Confocal images of iPSC-derived control and FTD-MAPT neurons (120 DIV; tau, green; MAP2, red; DAPI, blue). Hyperphosphorylated, AT8-positive tau (AT8; green) is found in cell bodies of FTD-MAPT neurons (arrows) but not in controls (β3-tubulin, red; DAPI, blue). Scale bars, 20 μm.(E) Increased co-localization of tau and MAP2 protein in FTD-MAPT neurons, compared with non-demented control neurons, analyzed by Pearson's R correlation (control lines, gray bars; FTD-MAPT lines, black).Significance was determined for three-sample comparison of non-demented control and two *MAPT* IVS10+16 lines using one-way ANOVA followed by Tukey's test (^∗^p \< 0.05 and ^∗∗∗^p \< 0.001). Pairwise comparison of the *MAPT* P301L line and its isogenic control was carried out using Student's t test (^∗^p \< 0.05); error bar represents SEM; n = 3 independent experiments.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Total tau content was similar in neurons of each genotype, collectively referred to here as FTD-MAPT neurons ([Figure 1](#fig1){ref-type="fig"}A). Notably, tau phosphorylation was increased in FTD-MAPT neurons compared with controls ([Figure 1](#fig1){ref-type="fig"}A), including at Ser404 and Ser202/Thr205 (AT8), epitopes typically hyperphosphorylated in tau-mediated dementias ([@bib2], [@bib54]). As both mutations are dependent on expression of exon 10 of *MAPT*, we confirmed translation of exon 10 in neurons generated from all iPSC lines by western blotting and mass spectrometry ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#mmc1){ref-type="supplementary-material"}). No significant difference in insoluble, aggregated tau was detected by sarkosyl extraction between neurons of each genotype ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Mislocalization of tau from axons to neuronal cell bodies and dendrites is an early event in FTD *in vivo* ([@bib24], [@bib27], [@bib33]). As expected, control neurons showed a predominantly axonal distribution of tau, with tau largely absent from MAP2-positive neuronal cell bodies and dendrites ([Figure 1](#fig1){ref-type="fig"}D). In contrast, tau was commonly present in MAP2-positive cell bodies and dendrites in both *MAPT* IVS10+16 and P301L neurons ([Figures 1](#fig1){ref-type="fig"}D and 1E). Furthermore, tau within cell bodies and dendrites of FTD-MAPT neurons was hyperphosphorylated, as detected by AT8-immunoreactivity (phospho-S202/T205) ([Figure 1](#fig1){ref-type="fig"}D).

Microtubules Invade the Nucleus in FTD-MAPT Neurons {#sec2.2}
---------------------------------------------------

Given the mislocalization of tau to the cell bodies of FTD-MAPT neurons, we studied neuronal microtubule dynamics in control and FTD-MAPT neurons ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). Actively extending microtubules were live-imaged in iPSC-derived neurons of each genotype by expression of GFP-tagged EB3 ([Figure 2](#fig2){ref-type="fig"}; [Videos S1](#mmc3){ref-type="supplementary-material"} and [S2](#mmc4){ref-type="supplementary-material"}), the microtubule plus-end binding protein (+TIP) ([@bib1]). Total microtubule movements were not different between non-demented control and FTD-MAPT neurons, with similar rates of extensions and retractions measured among the various genotypes ([Table S1](#mmc2){ref-type="supplementary-material"}).Figure 2Microtubules Invade the Nucleus in FTD-MAPT Neurons(A) Total microtubule trajectories (cumulative over a 200 s interval) overlaid on stills from GFP-EB3 live imaging (gray) demonstrate multiple microtubule extensions into the nuclei of FTD-MAPT neurons (*MAPT* IVS10+16-B and *MAPT* P301L; 120 DIV), compared with non-demented control neurons; white dotted line indicates the nuclear membrane.(B) GFP-EB3 growth tracks from representative neurons (cumulative over a 200 s interval) from FTD-MAPT neurons (*MAPT* IVS10+16-A/B and *MAPT* P301L) compared with non-demented and *MAPT* P301 isogenic control neurons (iPSC-derived neurons at 120 DIV; three biological replicates).Red arrows indicate examples of trajectories within the nucleus. Bars indicate the number of sampled neurons with (black), and without (white), nuclear EB3 growth tracks; n = number of imaged neurons. Scale bars, 10 μm.See also [Video S1](#mmc3){ref-type="supplementary-material"}, [Table S1](#mmc2){ref-type="supplementary-material"}, and [Figure S2](#mmc1){ref-type="supplementary-material"}.

Video S1. GFP-EB3 Comets in Control and FTD-*MAPT* iPSC-Derived Neurons, Related to Figure 2Videos obtained from live GFP-EB3 imaging of control (non-demented control and *MAPT* P301-isogenic) and familial FTD-*MAPT* (*MAPT* IVS10+16-A, *MAPT* IVS10+16-B and *MAPT* P301L) iPSCs-derived neurons, (100 DIV). Timing is indicated on the top right.

Video S2. GFP-EB3 Comets in FTD-*MAPT* IVS 10+16-A iPSC-Derived Neurons before and after Nocodazole Treatment, Related to Figure 2Videos obtained from live GFP-EB3 imaging of familial FTD-*MAPT* (*MAPT* IVS10+16-A) iPSCs-derived neurons, (100 DIV) before and after nocodazole (33μM) for two hours. Scale bar = 10 μm.

However, microtubule dynamics were qualitatively different in the cell bodies of control neurons compared with FTD-MAPT neurons. Non-demented control neurons typically had many actively growing microtubules within the cell body that extended around a smooth, oval nucleus ([Figures 2](#fig2){ref-type="fig"}A and 2B; [Video S1](#mmc3){ref-type="supplementary-material"}). In contrast, many FTD-MAPT neurons had microtubules with plus ends projecting into the nucleus (15 of 26 FTD-MAPT neurons) ([Figure 2](#fig2){ref-type="fig"}B), an event that was infrequently detected in both groups of control neurons (2 of 19) ([Figure 2](#fig2){ref-type="fig"}B). Notably, those microtubules that abnormally projected into the nucleus in FTD-MAPT neurons frequently originated from a pronounced focus that resembled a microtubule organizing center ([Figure 2](#fig2){ref-type="fig"}A; [Video S1](#mmc3){ref-type="supplementary-material"}). These pronounced foci were not detected in either of the control neuronal lines. We confirmed that the EB3+ microtubules that project into the neuronal nucleus are dynamically growing microtubules, as the mobility of EB3+ comets was greatly reduced following acute microtubule depolymerization (with nocodazole) ([Figures S2](#mmc1){ref-type="supplementary-material"}Band S2C; [Video S2](#mmc3){ref-type="supplementary-material"}).

Microtubules Deform the Nuclear Envelope in FTD-MAPT Neurons {#sec2.3}
------------------------------------------------------------

Microtubules couple to the nuclear membrane through the LINC complex ([@bib13]). This physical association results in transmission of mechanical forces that influence nuclear shape and integrity ([@bib11]), affecting the function of the nuclear envelope ([@bib55]). Given the abnormal projection of microtubules into the nucleus in FTD-MAPT neurons, we studied the shape of the nuclear envelope in iPSC-derived neurons. Marked differences were present in nuclear shape between non-demented controls and FTD-MAPT neurons, as demonstrated by large folds, or invaginations, of the laminB1-positive inner nuclear lamina within the nucleus ([Figure 3](#fig3){ref-type="fig"}). The neuronal identity of invaginated cells was confirmed by the co-staining with the cortical deep layer transcription factor CTIP2 and the pan-neuronal protein β3-tubulin ([Figure 3](#fig3){ref-type="fig"}).Figure 3Microtubules Deform the Nuclear Envelope in FTD-MAPT Neurons(A) Marked abnormalities of nuclear lamina shape in FTD-MAPT neurons. Confocal images of the nuclear lamina (laminB1, green) in FTD-MAPT neurons (*MAPT* IVS10+16-A/B and *MAPT* P301L; neuronal transcription factor CTIP2, red) compared with non-demented and *MAPT* P301 isogenic control neurons (120 DIV). White arrows indicate examples of nuclei with pronounced deformation of the nuclear lamina.(B) FTD-MAPT neurons have increased numbers of cells with deformed nuclear membranes, as defined by the shape of the inner nuclear lamina. Schematic of image analysis method used to quantify nuclear invaginations, as a measure of distortion of the nuclear membrane: nuclear area was established using DAPI (blue), and nuclear lamina (laminB1, green) was assigned as either nuclear boundary or invaginated (i.e., within the nucleus). The fraction of total laminB1 that was invaginated was used empirically to define a threshold for defining neurons as having nuclear membrane invaginations (see [Figure S3](#mmc1){ref-type="supplementary-material"} for details). Between 25% (*MAPT* P301L) and 40% (*MAPT* IVS10+16) of FTD-MAPT neurons have nuclear invaginations, compared with fewer than 10% of control neurons. Significance was determined for non-demented control and two *MAPT* IVS10+16 lines using one-way ANOVA followed by Tukey's test (^∗^p \< 0.05); pairwise comparison of the *MAPT* P301L line and its isogenic control was carried out using Student's t test (^∗^p \< 0.05); error bar represents SEM; n = 3 independent experiments.(C) Acute depolymerization of microtubules reverses nuclear lamina invaginations and restores rounded nuclear shapes. Confocal images of control and FTD-MAPT neurons (using genotypes described in A; 120 DIV), treated with DMSO (vehicle) or 10 μM nocodazole for 3 h (laminB1, green; β3-tubulin, red; DAPI, blue). Scale bars, 10 μm.(D) The proportion of FTD-MAPT neurons with nuclear lamina invaginations is significantly reduced by nocodazole treatment.Quantification of neurons with abnormalities of the nuclear lamina was carried out as in B. n = 3 independent experiments; error bars represent SEM. Significance was determined using one-way ANOVA followed by Tukey's test (^∗^p \< 0.05); error bar represents SEM; n = 3 independent experiments.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Quantification of the proportions of neurons with deformation of the nuclear membrane, as defined by the presence of laminB1-positive regions within the nucleus, ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}), demonstrated that deep nuclear invaginations were present in approximately 25% of *MAPT* P301L and 40% of *MAPT* IVS10+16 neurons, compared with fewer than 10% of control neurons ([Figure 3](#fig3){ref-type="fig"}B). To confirm that microtubules actively deformed the nucleus in FTD-MAPT neurons, we acutely depolymerized microtubule with the small molecule nocodazole. This significantly reduced the proportion of neurons with nuclear invaginations and restored round nuclear morphology ([Figures 3](#fig3){ref-type="fig"}C and 3D). We conclude that the pronounced deformations of the neuronal nuclear membrane in FTD-MAPT neurons are actively mediated by microtubules.

Super-resolution Imaging Demonstrates Close Apposition of Tau and Tubulin within Nuclear Lamina Invaginations {#sec2.4}
-------------------------------------------------------------------------------------------------------------

To further study the spatial relationships between tau, microtubules, and the nuclear envelope, we conducted a detailed analysis of the neuronal nucleus in iPSC-derived neurons using three-dimensional (3D) stimulated emission depletion (STED) super-resolution imaging. Three-dimensional STED imaging demonstrated that invaginations of the nuclear lamina present in FTD-MAPT neurons commonly extended deeply into the nucleus, in some cases traversing the entire length of the nucleus, forming pronounced folds ([Figure 4](#fig4){ref-type="fig"}A). In comparison, nuclei from non-demented controls had a regular, smooth morphology, with few examples of nuclear lamina invaginations ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Super-resolution Imaging Demonstrates Close Apposition of Tau and Tubulin within Nuclear Lamina Invaginations(A) Three-dimensional reconstructions using STED imaging of the nuclear lamina (laminB1, green) in FTD-MAPT iPSC-derived neurons (*MAPT* IVS10+16 and *MAPT* P301L) reveal pronounced nuclear invaginations compared with non-demented and MAPT P301-isogenic control neurons (120 DIV). Scale bar, 10 μm.(B) Tau is in close proximity to the nuclear lamina within nuclear invaginations of FTD-MAPT neurons. STED imaging of control and FTD-MAPT iPSC-derived neurons (using genotypes described in A; 120 DIV; tau, green; β3-tubulin, red; DNA, Yo-Pro, blue). Detail from white boxes in upper panels, showing both merge of all channels, and single channel images of tau (green) or β3-tubulin (red). Dashed lines indicate the boundary between the nucleus (Nu) and cytoplasm (Cy). Arrows indicate invaginations into the nucleus.(C) Nuclear invaginations are lined with nuclear lamina and contain tau. STED imaging of *MAPT* IVS10+16-A neurons (120 DIV; tau, green; laminB1, red). Arrow indicates tau within a nuclear invagination, in close proximity to the laminB1-positive inner nuclear lamina.

As observed by confocal microscopy, tau protein was found to be abundant in the cell bodies of FTD-MAPT neurons by STED imaging and in those neurons was closely apposed to the outer nuclear membrane ([Figure 4](#fig4){ref-type="fig"}B). Both tau protein and neuronal tubulin were found within nuclear lamina invaginations in FTD-MAPT neurons ([Figure 4](#fig4){ref-type="fig"}B). STED imaging demonstrated that tau within nuclear membrane invaginations is within hundreds of nanometers of the nuclear lamina ([Figure 4](#fig4){ref-type="fig"}C). Given that laminB1 filaments line the inner surface of the nuclear envelope, which is typically of the order of 15--60 nm in width ([@bib8], [@bib22]), we conclude that tau is in close proximity to proteins in the outer membrane of the nuclear envelope in FTD-MAPT neurons.

Tau-Containing Nuclear Lamina Invaginations in Neurons of the Post-mortem FTD-MAPT Cerebral Cortex {#sec2.5}
--------------------------------------------------------------------------------------------------

Having identified nuclear lamina defects in iPSC-derived FTD-MAPT neurons, we asked whether alterations of the nuclear lamina are also a feature of FTD-MAPT *in vivo*. To do so, we studied the incidence of invaginations of the nuclear lamina in the frontal and temporal cortex from two separate cohorts from independent brain banks, both containing individuals diagnosed with FTD due to *MAPT* IVS10+16 mutations and compared with age-matched non-demented controls. These cohorts were analyzed separately using different methods for detecting laminB1. We quantified the fraction of all nuclei with invaginations within each brain region ([Figure 5](#fig5){ref-type="fig"}). Similar results were obtained in both cohorts: the frequency of nuclear lamina invaginations was higher in the deep cortical layers in post-mortem cerebral cortices from individuals with FTD due to the *MAPT* IVS10+16 mutation, compared with non-demented control individuals ([Figures 5](#fig5){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). This was the case in both frontal and temporal cortex ([Figures 5](#fig5){ref-type="fig"}B, 5E, and 5F).Figure 5Tau-Containing Nuclear Lamina Invaginations in Neurons of the Post-mortem FTD-MAPT Cerebral Cortex(A) Increased incidence of laminB1-positive nuclear invaginations *in vivo*, in post-mortem FTD-MAPT IVS10+16 cortex compared with age-matched controls (cohort 1). Immunohistochemistry of laminB1 in (top) frontal and (bottom) temporal cortex from individuals with FTD due to the *MAPT* IVS10+16 mutation or age-matched controls (non-demented). Red arrows indicate nuclei exhibiting nuclear invaginations.(B) Percentage of invaginated nuclei in deep layers of frontal and temporal cortex of two control (green) and two *MAPT* IVS10+16 individuals (red), calculated from 20 individual imaging fields (cohort 1). Nuclei were scored by three observers, blinded to the identity of the post-mortem samples, and the averages of the three measurements are shown. Error represents SEM.(C) Hyperphosphorylated, AT8+ tau within nuclear lamina invaginations in neurons of the frontal (top) and temporal (bottom) cortex of an individual carrying *MAPT* IVS10+16 mutation. Representative neurons, showing an extensive nuclear invagination (laminB1, green; DAPI, gray) containing hyperphosphorylated tau (AT8, red). White arrows indicate nuclear invaginations. Scale bars, 10 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.(D) Representative confocal images from post-mortem FTD-MAPT IVS10+16 cortex compared with age-matched controls (cohort 2) showing laminB1 (red) and DAPI (blue); white arrows indicate nuclear invaginations. Scale bar, 10 μm.(E and F) Left: percentage of invaginated nuclei in deep layers of frontal (E) and temporal (F) cortex from six aged-matched controls and six FTD-MAPT IVS10+16 individuals (cohort 2) quantified using the analysis method described in [Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}. Points indicate quantifications from individual fields. Right: pairwise comparison of the control and FTD-MATP groups show increased percentage of invaginated nuclei in pathology (points indicate individuals; cohort 2) carried out using Student's t test (^∗∗∗^p \< 0.001); error bar represents SEM.

Data from iPSC-derived FTD-MAPT neurons suggested that laminB1-positive nuclear invaginations would be associated with the presence of phosphorylated tau within the neuronal cell body. Consistent with this, we found that the nuclear lamina was grossly disrupted in neurons that had high levels of hyperphosphorylated (AT8+) tau and neurofibrillary tangles in the post-mortem FTD-MAPT IVS10+16 cerebral cortex ([Figures 5](#fig5){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B), and those neurons frequently contained pronounced nuclear lamina invaginations ([Figures 5](#fig5){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B). Furthermore, nuclear lamina invaginations in such neurons also commonly contained AT8-positive hyperphosphorylated tau ([Figure 5](#fig5){ref-type="fig"}C).

Disrupted Nucleocytoplasmic Transport in FTD-MAPT Neurons {#sec2.6}
---------------------------------------------------------

Abnormalities of the nuclear lamina are also found in aging diseases, such as Hutchinson-Gilford progeria syndrome ([@bib7]). Nuclear membrane distortion in response to mechanical forces leads to deleterious effects on many aspects of nuclear function, disrupting nucleocytoplasmic transport ([@bib32]). We confirmed that the nuclear lamina/membrane invaginations present in iPSC-derived FTD-MAPT neurons also contained nuclear pores within these membrane folds, with nuclear pores (labeled by NUP98) co-localizing with laminB1-positive invaginations ([Figure S5](#mmc1){ref-type="supplementary-material"}A).

To assess whether alterations in the nuclear membrane in FTD-MAPT neurons result in defects in nucleocytoplasmic transport, we expressed NES:GFP and NLS:RFP from a single construct in iPSC-derived neurons ([@bib39]). This assay enables measurement of the integrity of both nuclear localization and accumulation and cytoplasmic retention and nuclear exclusion within individual neurons ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}B). Control iPSC-derived neurons had discrete cellular distributions of each protein, with prominent nuclear RFP and cytosolic GFP ([Figure 6](#fig6){ref-type="fig"}B). In contrast, localization of NLS:RFP was altered in FTD-MAPT neurons such that there was a marked decrease in the nuclear/cytoplasmic RFP ratio ([Figure 6](#fig6){ref-type="fig"}C). Conversely, nuclear exclusion of NES:GFP was reduced in FTD-MAPT neurons, with an increase of GFP within the nucleus ([Figure 6](#fig6){ref-type="fig"}C). Together, these data demonstrate defects in the selective permeability of the nuclear envelope in FTD-MAPT neurons, indicating a general failure of nucleocytoplasmic transport within FTD-MAPT neurons.Figure 6Disrupted Nucleocytoplasmic Transport in FTD-MAPT Neurons(A) Functional assay demonstrates disrupted nucleocytoplasmic transport in human iPSC-derived FTD-MAPT neurons. Schematic illustrates lentiviral vector for co-expression of NES:GFP (nuclear export signal fused to GFP) and NLS:RFP (nuclear localization signal fused to RFP) within human neurons and relative distributions of both proteins in healthy neurons and in cells with defective nucleocytoplasmic transport.(B) Representative confocal images of control and FTD-MAPT neurons (*MAPT* IVS10+16-A/B and *MAPT* P301L; all 120 DIV) expressing GFP:NES and RFP:NLS (GFP, green; RFP, red; β3-tubulin). Grayscale images of NES-GFP and NLS-RFP localization in representative cells of each genotype are shown: FTD-MAPT neurons show an increase of GFP within the nucleus and a reduction in nuclear localization of NLS-RFP. Scale bars, 20 μm.(C) Quantification of the nuclear/cytoplasmic ratio for both NES:GFP and NLS:RFP demonstrates altered nuclear transport in FTD-MAPT genotypes relative to controls: NES:GFP is increased in the nuclei of FTD-MAPT neurons, whereas NLS:RFP is decreased (points indicate quantifications from individual fields, different shapes indicate measurements from different experiments). Significance was determined for non-demented control and two *MAPT* IVS10+16 lines using one-way ANOVA followed by Dunnett's test (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001). Pairwise comparison of the *MAPT* P301L line and its isogenic control was performed using Student's t test (^∗^p \< 0.05); error bar represents SEM; n = 4 independent experiments.(D) Effect of nocodazole (Noc) on the nuclear/cytoplasmic ratio for both NES:GFP and NLS:RFP. Nuclear/cytoplasmic ratio is restored in the presence of nocodazole (+) in FTD-MATP neurons compared with vehicle (−) treated neurons (points indicate quantifications from individual fields, different shapes indicate measurements from different experiments).Significance was determined using one-way ANOVA followed by Dunnett's test (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001); error bar represents SEM; n = 3 independent experiments.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Defective nucleocytoplasmic transport may be a cumulative phenomenon due to protracted nuclear membrane damage, or an acute process due to microtubule-mediated nuclear membrane deformation. To distinguish between these mechanisms, we acutely depolymerized microtubules with nocodazole in control and FTD-MAPT neurons and quantified nucleocytoplasmic transport using the NES:GFP/NLS:RFP assay. This treatment corrected the distribution of both NES:GFP and NLS:RFP in FTD-MAPT neurons, restoring the nucleocytoplasmic ratios to the level of healthy control neuron ([Figure 6](#fig6){ref-type="fig"}D). We conclude that defective nucleocytoplasmic transport in FTD-MAPT neurons is an ongoing process due to microtubule-mediated deformation of the nuclear membrane.

Discussion {#sec3}
==========

The cellular and molecular biology of the pathogenesis of FTD due to *MAPT* mutations is not well understood. Currently, it is thought that *MAPT* mutations all lead to tau protein aggregation and that protein aggregation is the primary driver of neurodegeneration ([@bib4], [@bib48]). However, protein aggregation may represent only the late stage of the disease, and the processes preceding and leading to neurofibrillary tangle formation and cellular dysfunction remain to be elucidated. Here we report the use of human stem cell systems to study the effects of those mutations on neuronal cell biology, finding that tau-mediated dementias are accompanied by defective neuronal nucleocytoplasmic transport.

Focusing on two different types of *MAPT* mutations causal for FTD, we have found that both IVS10+16 and P301L mutations lead to marked defects in nucleocytoplasmic transport in human neurons. We find that both missense and splicing mutations in *MAPT* alter tau protein localization and phosphorylation within iPSC-derived neurons within 4 months in cell culture, recapitulating a well-described aspect of early FTD pathology *in vivo* ([@bib24], [@bib27], [@bib33]), without detectable tau aggregation. Mislocalization of tau in the cell bodies of FTD-MAPT neurons in culture leads to marked changes in microtubule dynamics, causing deformation of the nuclear membrane both in cell culture and in the human FTD-MAPT cortex *in vivo*. Disruption of the nuclear lamina is commonly associated with dysfunction of the nuclear envelope, and we find marked disruption of nucleocytoplasmic transport in FTD-MAPT neurons. Disrupted nucleocytoplasmic transport is due to ongoing microtubule-mediated nuclear membrane deformation, as it is corrected by acute microtubule depolymerization. Together, these data indicate that perturbation of the function of the nuclear membrane and disruption of nucleocytoplasmic transport is an important pathological process in FTD due to *MAPT* mutations.

An early event in FTD is the mislocalization of tau from axons to cell bodies and dendrites, and this key stage in disease progression is also an early event in iPSC-derived models of FTD-MAPT. *In vivo*, mislocalization of tau is typically associated with tau hyperphosphorylation ([@bib24], [@bib48]). We find this also occurs in iPSC-derived FTD-MAPT neurons, where we detected increased tau phosphorylation at serine 202/threonine 205 (the AT8 epitope) and also at serine 404. The sequence in which mislocalization and hyperphosphorylation take place in FTD *in vivo*, and in iPSC-derived FTD-MAPT neurons in culture, is not currently clear, nor are the mechanisms by which these processes occur. The appearance of tau within cell bodies and dendrites indicates a breakdown of the cellular polarity mechanisms that maintain the axonal enrichment of tau protein and its exclusion from the somatodendritic compartment, mechanisms that are poorly understood.

The two heterozygous, dominant *MAPT* mutations studied here have different effects on tau protein in neurons. The *MAPT* P301L missense mutation, like many missense mutations in the microtubule-binding region domain of *MAPT*, increases the tendency of tau to aggregate in cell-free assays and in transgenic mouse models ([@bib52], [@bib36], [@bib43]). In contrast, the IVS10+16 mutation is not a coding mutation but rather is an intronic single base change that favors the inclusion of exon 10 in the *MAPT* mRNA, increasing the amount of tau containing four microtubule-binding repeats (4R), relative to the three-repeat (3R) form ([@bib28]). However, despite these differences, the changes in the forms of tau in both *MAPT* P301L and IVS10+16 neurons both lead to mislocalization and increased phosphorylation of tau. This finding suggests that either the presence of a pool of P301L tau, or a shift in the 3R/4R tau ratio, alter a common pathway that regulates tau distribution within neurons, tau phosphorylation, or both.

In both *MAPT* IVS 10+16 and P301L mutant neurons, the appearance of tau in cell bodies is accompanied by marked qualitative changes in neuronal microtubule dynamics. Microtubules in FTD-MAPT neurons actively deform the nuclear envelope, which we find can be reversed by depolymerization of microtubules. Tau has multiple roles in stabilizing microtubules ([@bib53]), and microtubules are coupled to the nuclear membrane through the LINC complex ([@bib11], [@bib13], [@bib38]). Therefore, it is likely that the overall effect of the presence of tau in the cell body is to promote microtubule stability, leading to increased pushing forces on the nuclear membrane and the formation of invaginations in the nuclear membrane. As tau has recently also been found to promote microtubule nucleation when undergoing phase transitions at high concentration ([@bib26]), accumulation of tau in the cell body may also lead to increased pushing forces on the nucleus by facilitating microtubule nucleation.

Alterations in nuclear shape and nuclear membrane function are a common feature of cellular aging, including in the nervous system, and are associated with multiple deleterious changes in nuclear biology, including chromatin changes and disrupted nucleocytoplasmic transport ([@bib19], [@bib40]). *Drosophila* models of FTD, with neuronal expression of human *MAPT* R406W, have nuclear shape abnormalities and chromatin changes ([@bib20]). Recently, nuclear membrane disruption has been reported in a *MAPT* P301L transgenic mouse model of FTD ([@bib16]). Perturbations of the nuclear lamina have been described in the post-mortem AD brain ([@bib20]), including the juxtaposition of neurofibrillary tangles of tau with the nuclear membrane ([@bib44]). We also find here an increase in nuclear invaginations in neurons of the human post-mortem *MAPT* IVS10+16 cortex, and the presence of hyperphosphorylated tau within nuclear invaginations in tangle-bearing neurons. Together, these different studies are consistent with a pathological effect of tau within the neuronal cell body in FTD and AD, whereby the presence of tau alters microtubule biology, resulting in pronounced abnormalities of the neuronal nucleus and defective nucleocytoplasmic transport. Recent findings have shown a direct interaction of aggregated tau with the nuclear pore complex ([@bib16]), suggesting that the microtubule disruption of nuclear pore function reported here may be mediated by tau protein at the nuclear membrane.

Microtubule deformation of the nucleus is a phenotype also seen in classic laminopathies such as the accelerated aging disorder Hutchinson-Gilford progeria syndrome (HGPS), in which the primary defect is due to mutant lamin A/C protein ([@bib10]). In that case, microtubules also contribute to nuclear deformations, leading to defects in nucleocytoplasmic transport ([@bib32], [@bib34], [@bib47]). Changes in nuclear envelope function in other neurodegenerative diseases, including ALS-FTD due to repeat expansions in *C9orf72*, Huntington's disease, and AD, have recently been reported ([@bib18], [@bib25], [@bib30], [@bib58]).

Our finding here of disruption of the neuronal nuclear membrane as a consequence of *MAPT* mutations in FTD extends this pathogenic mechanism to dementias in which protein aggregation has been thought to be the primary driver of neurodegeneration. These data suggest that dysfunction of the nuclear membrane may be a common pathogenic process in diverse neurodegenerative diseases, which could be targeted therapeutically with agents that regulate microtubule functions, nucleocytoplasmic transport, and/or associated processes.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**4R-tau; rabbitCosmo BioCat\#CAC-TIP-4RT-P01; RRID:N/AAlexa Fluor 488 donkey anti-rabbitThermo Fisher ScientificCat\#A21206; RRID:[AB_2535792](nif-antibody:AB_2535792){#interref45}Alexa Fluor 488 goat anti-chickenThermo Fisher ScientificCat\#A11039; RRID:[AB_142924](nif-antibody:AB_142924){#interref50}Alexa Fluor 594 donkey anti-mouseThermo Fisher ScientificCat\#A21203; RRID:[AB_141633](nif-antibody:AB_141633){#interref55}Alexa Fluor 647 donkey anti-rabbitThermo Fisher ScientificCat\#A31573; RRID:[AB_2536183](nif-antibody:AB_2536183){#interref60}Alexa Fluor 647 goat anti-ratThermo Fisher ScientificCat\#A21247; RRID:[AB_141778](nif-antibody:AB_141778){#interref65}CTIP2; rat monoclonalAbcamCat\#ab18465; RRID:[AB_10015215](nif-antibody:AB_10015215){#interref70}GFP; chicken polyclonalAbcamCat\#ab13970; RRID:[AB_300798](nif-antibody:AB_300798){#interref75}IRDye 680 RD donkey anti-mouseLI-COR bioscienceCat\#925-68072; RRID:N/AIRDye 800 CW donkey anti-rabbitLI-COR bioscienceCat\#926-32213; RRID:[AB_621848](nif-antibody:AB_621848){#interref80}LaminB1 \[119D5-F1\]; mouse monoclonalAbcamCat\#ab8982; RRID:[AB_1640627](nif-antibody:AB_1640627){#interref85}LaminB1; rabbit polyclonalAbcamCat\#ab16048; RRID:[AB_443298](nif-antibody:AB_443298){#interref90}MAP2; chicken polyclonalAbcamCat\#ab5392; RRID:[AB_2138153](nif-antibody:AB_2138153){#interref95}NUP98; rat monoclonalAbcamCat\#ab50610; RRID:[AB_881769](nif-antibody:AB_881769){#interref100}Phospho-tau pS202/T205 - AT8; mouse monoclonalThermo Fisher ScientificCat\#MN1020; RRID:[AB_223647](nif-antibody:AB_223647){#interref105}Phospho-tau S404; rabbit monoclonalAbcamCat\#ab92676; RRID:[AB_10561457](nif-antibody:AB_10561457){#interref110}tau RD3; mouse monoclonalMilliporeCat\#05-803; RRID:[AB_310013](nif-antibody:AB_310013){#interref115}Tbr1; rabbit polyclonalAbcamCat\#ab31940; RRID:[AB_2200219](nif-antibody:AB_2200219){#interref120}total tau HT7; mouse monoclonalThermo Fisher ScientificCat\#MN1000; RRID:[AB_2314654](nif-antibody:AB_2314654){#interref125}total tau; rabbit polyclonalDako CytomationCat\#A0024; RRID:[AB_10013724](nif-antibody:AB_10013724){#interref130}β-actin; mouse monoclonalSigmaCat\#A2228; RRID:[AB_476697](nif-antibody:AB_476697){#interref135}β3-tubulin; mouse monoclonalBioLegendsCat\#MMS-435P; RRID:[AB_2313773](nif-antibody:AB_2313773){#interref140}**Biological Samples**Human brain FFPE sections from frontal and temporal cortex (cohort 1)Queen's Square Brain Bank, Institute of Neurology, University College LondonTissue request MTA ID 20170112_UCLHuman brain FFPE sections from frontal and temporal cortex (cohort 2)London Neurodegenerative Diseases Brain Bank and Brains for Dementia ResearchTissue request No 1827**Chemicals, Peptides, and Recombinant Proteins**2-MercaptoethanolThermo Fisher ScientificCat\#21985-023AccutaseInnovative Cell TechnologiesCat\#AT104B-27 supplementThermo Fisher ScientificCat\#17504-044Bovine Serum Albumin (BSA)SigmaCat\#A2153cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail TabletsSigmaCat\#04693159001Colloidal Blue Staining KitThermo Fisher ScientificCat\#LC6025DAB Peroxidase (HRP) Substrate KitVector LaboratoriesCat\#SK-4100DAPISigmaCat\#D9542DispaseThermo Fisher ScientificCat\#17105DL-Dithiothreitol solutionSigmaCat\#646563DMEM/F-12, GlutaMAXThermo Fisher ScientificCat\#31331-028DNase INew England BioLabsCat\#M0303SDimethyl sulfoxide (DMSO)SigmaCat\#D2650Donkey serumAbcamCat\#ab7475Dorsomorphin dihydrochlorideTocrisCat\#3093Essential 8 mediumThermo Fisher ScientificCat\#A1517001Fibroblast growth factor 2 (FGF2)PeproTechCat\#100-18BHalt Phosphatase Inhibitor CocktailThermo Fisher ScientificCat\#78420High Capacity cDNA Reverse Transcription kitThermo Fisher ScientificCat\#4368814InsulinSigmaCat\#19278L-GlutamineThermo Fisher ScientificCat\#25030-024LamininSigmaCat\#L2020N-2 supplementThermo Fisher ScientificCat\#17502-048N-Lauroylsarcosine sodium salt solutionSigmaCat\#61747NeurobasalThermo Fisher ScientificCat\#12348-017NocodazoleTocrisCat\#1228Non-essential amino acid solutionThermo Fisher ScientificCat\#11140-050NuPAGE LDS Sample BufferThermo Fisher ScientificCat\#NP0007Paraformaldehyde (PFA)SigmaCat\#158127PBSN/AN/APenicillin-streptomycinThermo Fisher ScientificCat\#15140-122Phenylmethanesulfonyl fluoride (PMSF) solutionSigmaCat\#93482ProLong Gold Antifade MountantThermo Fisher ScientificCat\#P36930RIPA BufferSigmaCat\#R0278SB431542Tocris BioscienceCat\#1614Sodium pyruvateSigmaCat\#S8636Sudan Black BSigmaCat\# 199664SYBR Green JumpStart Taq Ready MixSigmaCat\#S4438Triton X-100SigmaCat\#T8787TRIzolThermo Fisher ScientificCat\#15596026Tween 20SigmaCat\#P9416Trisodium citrate dihydrateSigmaCat\#S1804**Critical Commercial Assays**Precision Red Advanced Protein AssayCytoskeleton, Inc.Cat\# ADV02-A**Experimental Models: Cell Lines**Human: non-demented control (NDC) iPSC line[@bib29]N/AHuman: MAPT IVS10+16-A and MAPT IVS10+16-B iPSC lines[@bib49]N/AHuman: MAPT P301L and MAPT P301L-isogenic iPSC linesJanssen PharmaceuticaIMI STEMBANCC project agreement ICD 483960**Oligonucleotides**4RMAPT For 5′ -- AAGATCGGCTCCACTGAGAA -- 3′This paperN/A4RMAPT Rev 5′ -- CACACTTGGACTGGACGTTG -- 3′This paperN/AGAPDH For 5′ -- AATGAAGGGGTCATTGATGG -- 3′This paperN/AGAPDH Rev 5′ -- AAGGTGAAGGTCGGAGTCAA -- 3′This paperN/ARPS9 For 5′ -- CAGCTTCATCTTGCCCTCAT -- 3′This paperN/ARPS9 Rev 5′ -- CTGCTGACGCTTGATGAGAA -- 3′This paperN/A**Recombinant DNA**dsEGFP-EB3-7Michael DavidsonAddgene plasmid \# 56474; RRID:Addgene_56474pLVX-EF1alpha-2xGFP:NES-IRES-2xRFP:NLS[@bib39]Addgene plasmid \#71396; RRID:Addgene_71396**Software and Algorithms**ABI StepOnePlus softwareThermo Fisher ScientificN/A; RRID:N/AFiji[@bib42]RRID:[SCR_002285](rridsoftware:SCR_002285){#interref145}Image Studio LiteLI-COR**RRID**:[SCR_013715](rridsoftware:SCR_013715){#interref150}MascotMATRIX ScienceRRID:[SCR_014322](rridsoftware:SCR_014322){#interref155}plusTipTracker[@bib3]N/A; RRID:N/APrism 6GraphPadRRID:[SCR_002798](rridsoftware:SCR_002798){#interref160}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rick Livesey (<r.livesey@ucl.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human iPSC lines {#sec4.3.1}

*MAPT* IVS10+16-A and *MAPT* IVS10+16-B mutant iPSCs were as reported in ([@bib49]). *MAPT* P301L was generated from Janssen Pharmaceutica by TALEN editing the line *MAPT* P301-isogenic, under the IMI STEMBANCC project agreement ICD 483960. The non-demented control line was previously reported ([@bib29]). iPSC cells were growth and expanded in feeder-free conditions using Essential 8 Medium (Thermo Fisher Scientific), at 37°C with 5% CO~2~. Essential 8 Medium was replaced daily.

### Human post-mortem brain sections {#sec4.3.2}

Human brain sections were obtained from the Queen's Square Brain Bank, Institute of Neurology, University College London (cohort one) and from the London Neurodegenerative Diseases Brain Bank and Brains for Dementia Research (cohort two). For cohort one, control brains included one male (age 71) and one female (age 56). FTD-MAPT IVS10+16 brains were from two males (age 52 and 66). For cohort two, control brains were from five males (age 63-77) and one female (age 43). FTD-MAPT IVS10+16 brains were from four males (age 48-71) and two females (age 58 and 63). The use of human post-mortem tissues for this study has been approved with Research Ethics Committee reference ID 08/H0718/54+5 for cohort one and reference ID 08/MRE09/38+5 for cohort two.

Method Details {#sec4.4}
--------------

### Generation of iPSC-derived cortical neurons and drug treatments {#sec4.4.1}

Differentiation of iPSCs to cortical neurons was carried out as described, with minor modifications ([@bib46], [@bib45]). Briefly, dissociated iPSCs were plated on Geltrex (Thermo Fisher Scientific)-coated plates to reach full confluence. Neural induction was initiated the next day (Day 0) by changing the culture medium to a 1:1 mixture of DMEM/N-2 (DMEM/F-12 GlutaMAX; 1 × N-2; 5 μg ml^−1^ insulin; 1 mM L-glutamine; 100 μm non-essential amino acids; 100 μM β-mercaptoethanol; 50 U ml^−1^ penicillin and 50 mg ml^−1^ streptomycin) and Neurobasal/B-27 (Neurobasal; 1 × B-27; 200 mM L-glutamine; 50 U ml^−1^ penicillin and 50 mg ml^−1^ streptomycin) media (hereafter referred as N2B27) supplemented with 1 μM dorsomorphin and 10 μM SB431542 to inhibit TGFβ signaling and support neuronal differentiation and neurogenesis, media was replaced every 24 hours. At day 12 neuroepithelial sheet was harvested and dissociated using the enzyme Dispase and replated on laminin-coated plates. The day after, media was replaced with N2B27 containing 20 ng/mL FGF2. N2B27+FGF2 was added freshly daily for 4 days to promote the maturation of neural rosettes. After 4 days FGF2 was withdrawn and neural rosettes were maintained in N2B27 refreshing medium every other day. At day 30 neural rosettes were dissociated using Accutase and neural progenitor cells were plated on laminin-coated plates at 150,000 cells/mm^2^. Plated neurons were maintained for up to 120 days with a medium change every other day. To establish identity and quality of cortical neuronal inductions, gene expression profiling was performed on a custom gene expression panel. RNA was isolated from induced cortical neurons using TRIzol (Thermo Fisher Scientific), according to the manufacturer's instructions. Expression levels of mRNAs enriched in deep and upper layer cortical neurons were assessed using a nanoString (nanoString Technologies) gene expression panel of approximately 250 genes. After subtracting the maximum negative control probe counts, gene counts were normalized using the geometric mean of 6 positive control probes and of 7 housekeeping genes (CLTC, GAPDH, GUSB, PPIA, RPLP1, RPS15A, RPS9). For nocodazole (Tocris) treatment, neurons were grown for 120 days *in vitro* (DIV) and compound was added at 33 μM for 2 hours before imaging. DMSO was used as vehicle.

### Protein extraction and western blot analysis {#sec4.4.2}

Total cell protein was extracted using RIPA buffer (Sigma) supplemented with protease inhibitors (Sigma) and Halt phosphatase inhibitors (Thermo Fisher Scientific). Protein quantification was performed using Precision Red Advanced Protein Assay buffer (Cytoskeleton, Inc.). For each sample, 30 μg of protein were mixed with 1X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) + 1 μM Dithiothreitol. Samples were heated at 100°C for 10 minutes and loaded on NuPAGE 4%--12% Bis-Tris gel (Thermo Fisher Scientific). Afterward, proteins were transferred on PVDF membrane (Millipore) for 1 h at 100 V. Membranes were blocked for another 60 min in 5% BSA in PBST (PBS containing 0.05% Tween 20). All primary antibodies were incubated overnight in 5% milk in PBST at 4°C. Next day, membranes were incubated for at least 1 h in secondary antibody and washed gently in PBST buffer for further 30-60 min. Immunoblots were detected using LI-COR Odyssey CLx Infrared Imaging System and processed with the Image Studio Software (LI-COR).

### Sarkosyl extraction {#sec4.4.3}

iPSC-derived neurons (120 DIV) were homogenized in Tris-NaCl buffer (25 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM Na~4~P~2~O~7~, pH 7.6) supplemented with 1 mM PMSF, protease inhibitors (Sigma) and Halt phosphatase inhibitors (Thermo Fisher Scientific). Homogenate was subjected to ultracentrifugation at 150,000 g for 30 min at 4°C. The pellet was re-suspended in an equal volume of 10 mM TrisHCl, 0.8 M NaCl, 10% sucrose, pH 7.6 supplemented with 1 mM PMSF, protease inhibitors and Halt phosphatase inhibitors. The re-suspended pellet was centrifuged at 20,000 g for 30 min at 4°C, the supernatant was incubated with 1% sarkosyl (N-lauroylsarkosine sodium salt; Sigma) for 1 hour at room temperature and ultracentrifuged at 150,000 g for 30 min at 4°C. The resulting pellet (sarkosyl insoluble fraction) was resuspended in 1X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) + 1 mM Dithiothreitol. Samples were heated at 100°C for 10 minutes and loaded on NuPAGE 4%--12% Bis-Tris gel (Thermo Fisher Scientific).

### Immunoprecipitation and mass spectrometric analysis of intracellular tau {#sec4.4.4}

Tau was immunoprecipitated from 1 mg of total protein extracted from iPSC-derived neurons (120 DIV) using a polyclonal anti-tau antibody (Dako Cytomation). Immunoprecipitated samples were analyzed by western blot using a monoclonal tau antibody (MN1000; Thermo Fisher Scientific) or stained with colloidal blue (Thermo Fisher Scientific). Bands that corresponded to tau by western blot analysis were excised from the colloidal blue SDS-PAGE. Peptide masses of digested protein samples were determined using a Bruker ultrafleXtreme Maldi mass spectrometer in reflectron mode and ms/ms fragmentation performed in LIFT mode. Data analysis was with FlexAnalysis, BioTools and ProteinScape software (Bruker). Database searches of the combined mass fingerprint-ms/ms data were performed using Mascot (<http://www.matrixscience.com>).

### RNA extraction and qRT-PCR analysis {#sec4.4.5}

Total RNA was extracted using TRIzol according to manufacturer protocol (Invitrogen). 1 μg of RNA was treated with DNase I (New England BioLabs) and 500 ng were retrotranscribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qRT-PCR were performed in a StepOnePlus instrument (Applied Biosystems) using the SYBR Green JumpStart Taq Ready Mix (Sigma) in a final volume of 15 μl, using the following protocol: 95°C for 2 min, 40 cycles at 94°C for 15 s, 60°C for 30 s. *MAPT* mRNA expression was assessed relative to *GAPDH* and *RPS9* housekeeping genes using the specific primers reported in the Key Resource Table. Results were analyzed using the ABI StepOnePlus software (Thermo Fisher Scientific).

### Confocal microscopy and image analysis {#sec4.4.6}

For immunofluorescent labeling and imaging, cells were washed 3 times in PBS and then fixed using 4% paraformaldehyde (v/v) in PBS for 15 minutes at RT. After 3 washes in PBS, cells were permeabilised in PBS+0.3% Triton X-100 (Sigma; Tx) for 15 minutes at room temperature (RT). After 3 washes in PBS, cells were blocked using 5% donkey serum in PBS+0.3% Triton X-100 (PBS-Tx+5% DS) for 1 hr at RT. For AT8-tau immunostaining (ThermoFisher; MN1020), 5% BSA (Sigma) (w/v) in PBS+0.3% Triton X-100 (PBS-Tx+5% BSA) was used as a blocking agent. Primary antibodies were diluted in PBS-Tx+5% DS or PBS-Tx+5% BSA as indicated below and incubated overnight at 4°C. Cells were washed 3 times in PBS and incubated 1 hr in the dark at RT with secondary antibodies diluted 1:1000 in PBS-Tx+5% DS or PBS-Tx+5% BSA. After 3 washes in PBS, samples were incubated for 5 minutes at RT with DAPI diluted 1:5000 in PBS and then washed 3 additional times with PBS. Samples were mounted using ProLong Gold antifade (Thermo Fisher Scientific).

Standard confocal images were acquired with an Olympus Inverted FV1000 confocal microscope and processed using Fiji software ([@bib42]). STED imaging was performed on a custom built, dual color, beam scanning system with gated detection optically identical to the instrument described in ([@bib6]).

For image analysis of colocalization of tau and MAP2, Pearson's R correlation was calculated using the Coloc2 plugin for Fiji (<https://imagej.net/Coloc2>). To quantify nuclear invaginations neurons were co-stained for LaminB1 and DAPI. Nuclear lamina signal was assigned as either nuclear boundary or invaginated (i.e., within the DAPI stained area defining the nucleus) using a custom plugin for the Fiji bioimage analysis software. Nuclei with a proportion of invaginated laminB1 that exceeded 0.3 were considered as invagination positive (see [Figure 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"} for details). At least 5 imaging fields from three independent experiments for genotype were analyzed.

### Staining of human formalin-fixed paraffin embedded (FFPE) brain sections {#sec4.4.7}

FFPE slides were deparaffinised and rehydrated, then boiled for 20 minutes in 10 mM Tri-sodium citrate buffer, pH6 + 0.05% Tween 20, for antigen retrieval. Slides were cooled to RT before staining. 3,3′-Diaminobenzidine (DAB) staining was performed using the DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories) according to manufacturer's instructions. After DAB staining, whole sections were imaged using an Axio Scan.Z1 microscope (Zeiss). For immunofluorescence, after antigen retrieval slides were blocked using 5% BSA in PBS+0.3% Triton X-100 (PBS-Tx+5% BSA) for 20 minutes at RT. Primary antibodies were diluted in PBS-Tx+5% BSA as indicated below and incubated O/N at 4°C in humidified chamber. Slides were washed 3 times in PBS and incubated for 30 minutes in the dark at RT with secondary antibodies diluted 1:1000 in PBS-Tx+5% BSA. After 3 washes in PBS, samples were incubated 5 minutes with DAPI diluted 1:5000 in PBS. After 3 washes in PBS, slides were incubated for 20 minutes with 0.01% Sudan Black B (Sigma) in 70% ethanol. Samples were mounted using ProLong Gold antifade (Thermo Fisher Scientific). Images were acquired through Olympus Inverted FV1000 confocal microscope and processed using the Fiji software.

For cohort one, nuclear lamina invaginations were quantified after 3,3′-Diaminobenzidine (DAB) staining of LaminB1. Nuclei were scored from 20 randomly acquired imaging fields from each individual. Nuclei were considered positive (folded) if invaginations extended into the nuclear interior for at least 3 μm. The percentage of folded respect to total nuclei was calculated for each imaging field. For cohort two, neurons were co-stained for LaminB1 and DAPI. Nuclear lamina signal was assigned as either nuclear boundary or invaginated (i.e., within the DAPI stained area defining the nucleus) using custom plugin for the Fiji bioimage analysis software. Nuclei with a proportion of invaginated laminB1 that exceeded 0.3 were considered as invagination positive (see [Figure 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"} for details).

### Live imaging of microtubule dynamics {#sec4.4.8}

Neurons were grown to 100 DIV in individual μ-Dish 35 mm dishes (Ibidi) and transfected with a plasmid encoding for GFP-EB3 (gift from Michael Davidson; Addgene plasmid \# 56474). 48h after transfection, neurons were subjected to live imaging using a Leica SP5 microscope equipped with a controlled environment chamber (37°C; 5% CO~2~). Images were acquired at resonant scanning with a 63x objective (1frame/sec). Resulting movies were analyzed using the plusTipTracker software ([@bib3]).

### Nucleocytoplasmic transport assay {#sec4.4.9}

Nucleocytoplasmic trafficking was analyzed by infection of 120 DIV human iPSC-derived neurons with the pLVX-EF1alpha-2xGFP:NES-IRES-2xRFP:NLS construct (Addgene plasmid \#71396; [@bib39]). After 6 days, neurons were fixed and immunostained for β3-tubulin and GFP. Only cells positive for neuron-specific β3-tubulin were considered. The nuclear to cytoplasmic ratios of both GFP and RFP (nucRFP:cytRFP and nucGFP:cytGFP) were calculated separately using the integrated density of ROIs drawn within and outside the nucleus (see [Fig.S5](#mmc1){ref-type="supplementary-material"} for details).

Quantification and statistical analysis {#sec4.5}
---------------------------------------

Unless otherwise specified, data are presented as mean values of the number of independently conducted experiments indicated in the legend of each figure. Error bars represent the standard error of mean (SEM). Statistical analysis was performed using the Prism6 analytical software (GraphPad). Unpaired Student's t test was used to compare differences between two groups, assuming the data were normally distributed. One-way ANOVA followed by Tukey's or Dunnett's correction for multiple testing (as indicated in figure legends) was used to analyze the differences between more than two groups. ^∗∗∗^ p \< 0.01, ^∗∗^p \< 0.01, ^∗^p \< 0.05.
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